RSVpreF + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lower Respiratory Tract Illness
Conditions
Lower Respiratory Tract Illness
Trial Timeline
Aug 31, 2021 → Jan 18, 2027
NCT ID
NCT05035212About RSVpreF + Placebo
RSVpreF + Placebo is a phase 3 stage product being developed by Pfizer for Lower Respiratory Tract Illness. The current trial status is active. This product is registered under clinical trial identifier NCT05035212. Target conditions include Lower Respiratory Tract Illness.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06866405 | Phase 3 | Recruiting |
| NCT05035212 | Phase 3 | Active |
| NCT04424316 | Phase 3 | Completed |
Competing Products
20 competing products in Lower Respiratory Tract Illness